HMP Global

Oncology Learning Network

Health EN ↓ 191 episodes

Podcast by HMP Global

Be sure to visit the podcast's website and support the creator: soundcloud.com

Author

HMP Global

Category

Health

Podcast website

soundcloud.com

Latest episode

Nov 4, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Cholangioscopy: What Interventional Oncologists Need to Know Part 2 21.08.2024

Three cholangioscopy experts join Elena Violari, MD, RPVI for this episode of the SIO Corner.

Cholangioscopy: What Interventional Oncologists Need to Know 21.08.2024

Three cholangioscopy experts join Elena Violari, MD, RPVI for this episode of the SIO Corner.

Applications of AR in Interventional Oncology 20.06.2024

Applications of AR in Interventional Oncology by HMP Global

How Artificial Intelligence May Change Interventional Oncology 16.04.2024

Dania Daye, MD, PhD, joins the SIO Corner podcast to discuss the ways AI may be applied in interventional oncology.

Sacituzumab Govitecan Plus Pembrolizumab in the TROPHY-U-01 Trial 07.03.2024

Petros Grivas, MD, PhD, discusses the combination of sacituzumab govetican and pembrolizumab for metastatic urothelial carcinoma in the second-line setting.

Episode 1: Maintenance Rituximab for Waldenström Macroglobulinemia 07.02.2024

On this episode of Blood Bytes, a hematology podcast produced by Oncology Learning Network, Steven Treon, MD, PhD, Director of the Bing Center for Waldenström’s macroglobulinemia at the Dana-Farber Cancer Institute, and Professor of Medicine at Harvard Medical School, Boston, sits down with Christian Buske, MD, Medical Director at the Comprehensive Cancer Center and the Institute of Experimental C...

Neoadjuvant Chemotherapy Plus HER2-Targeted Therapy for Early Stage HER2-Positive Breast Cancer 16.02.2023

Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.

Advances in Gastrointestinal Genetic Testing 20.12.2022

Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.

Enfortumab Vedotin for Metastatic Urothelial Cancer After Progression on Platinum-Based Chemotherapy 15.11.2022

Petros Grivas, MD, shares his treatment plan for a patient with metastatic urothelial cancer who has progressed following platinum-based chemotherapy.

BRCAness May Predict Response to Platinum-Based Chemotherapy in Intrahepatic Cholangiocarcinoma 29.07.2022

Margherita Rimini, MD, discusses the potential link between BRCAness phenotype and response to platinum-based chemotherapy in cholangiocarcinoma.

Durvalumab Conveys Benefit for All Biliary Tract Cancer Types 22.07.2022

Ruth He, MD, discusses findings from a subgroup analysis assessing outcomes by primary tumor location in biliary tract cancer treated with durvalumab.

Pemigatinib for Cholangiocarcinoma with FGFR2 Fusions or Rearrangements 14.07.2022

Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.

Maintenance Cabozantinib in Metastatic Urothelial Carcinoma 22.06.2022

Robert Jones, MD, University of Glasgow, UK, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following chemotherapy for patients with metastatic urothelial carcinoma who were negative for DNA repair biomarkers

Sacituzumab Govitecan Plus Pembrolizumab for Platinum-Refractory Metastatic Urothelial Cancer 22.06.2022

Petros Grivas, MD, from the University of Washington Fred Hutchinson Cancer Research Center, shares results from the TROPHY-U-01 phase 2 trial evaluating the use of sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.

Part 2: Overcoming PARP Inhibitor and Platinum Resistance in Patients With Ovarian Cancer 20.06.2022

Part 2: Overcoming PARP Inhibitor and Platinum Resistance in Patients With Ovarian Cancer by HMP Global

Part 1: Current Emerging Therapies for Platinum-Resistant Ovarian Malignancies With Dr O'Mally 26.05.2022

Stay tuned for Part 2!

Therapeutic Advances and Considerations for Treatment Selection in High-Risk AML 13.04.2022

Guenther Koehne, MD, PhD, interviews Richard Stone, MD; Robert Soiffer, MD; and Siddhartha Mukherjee, MD, on recent therapeutic advances for hematologic malignancies with a focus on considerations for treatment selection in high-risk AML.

Ibrutinib Improves Outcomes Over Rituximab Among Patients With Advanced CLL/SLL 06.04.2022

Shenmiao Yang, MD, highlights a multicenter, phase 3 trial comparing ibrutinib versus rituximab for advanced CLL/SLL, in which ibrutinib outperformed rituximab in all therapy outcomes.

Evolving Roles of KRAS Inhibitors in CRC 31.03.2022

Evolving Roles of KRAS Inhibitors in CRC by HMP Global

The Role of Tumor Mutation Burden Featuring Dr Morris 31.03.2022

The Role of Tumor Mutation Burden Featuring Dr Morris by HMP Global

Dr Morris Discusses Emerging Targeted Therapies in mCRC 31.03.2022

Dr Morris Discusses Emerging Targeted Therapies in mCRC by HMP Global

Dr Lieu Talks ctDNA to Guide CRC Treatment 29.03.2022

Christopher Lieu, MD, University of Colorado, shares insights to how ctDNA can detect MRD and determine genomic characterization of tumors in CRC.

Dr Casulo Overviews Approved Treatment Options to Manage Newly Diagnosed, Relapsed FL 23.03.2022

Carla Casulo, MD, Associate Professor, Wilmot Cancer Institute, University of Rochester, New York, overviews the various treatments that have been approved for the management of patients with newly diagnosed and relapsed follicular lymphoma (FL).

Dr Batlevi Shares Promising Data of Tazemetostat from SYMPHONY-1 Trial 21.03.2022

Connie Batlevi, MD, PhD shares updated safety and efficacy data from the SYMPHONY-1 trial of tazemetostat, a first-class, oral, selective EZH2 inhibitor, for patients with FL.

Dr Loprinzi Reviews Hot Flash Treatment Strategies in BC, Part II 15.03.2022

Dr Loprinzi Reviews Hot Flash Treatment Strategies in BC, Part II by HMP Global

Listen to the Oncology Learning Network podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.